Indivior PLC Ordinary Shares (INDV)vsUnited Therapeutics Corporation (UTHR)
INDV
Indivior PLC Ordinary Shares
$35.43
+5.10%
HEALTHCARE · Cap: $4.45B
UTHR
United Therapeutics Corporation
$549.87
+0.40%
HEALTHCARE · Cap: $23.17B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 146% more annual revenue ($3.17B vs $1.29B). UTHR leads profitability with a 40.6% profit margin vs 19.5%. INDV trades at a lower P/E of 19.3x. INDV earns a higher WallStSmart Score of 62/100 (C+).
INDV
Buy62
out of 100
Grade: C+
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INDV.
Margin of Safety
+2.5%
Fair Value
$487.82
Current Price
$549.87
$62.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 46.1%
Earnings expanding 82.0% YoY
Conservative balance sheet, low leverage
19.2% revenue growth
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
Negative free cash flow — burning cash
Distress zone — elevated risk
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : INDV
The strongest argument for INDV centers on Operating Margin, EPS Growth, Debt/Equity. Profitability is solid with margins at 19.5% and operating margin at 46.1%. Revenue growth of 19.2% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : INDV
The primary concerns for INDV are Free Cash Flow, Altman Z-Score.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
INDV profiles as a growth stock while UTHR is a declining play — different risk/reward profiles.
INDV carries more volatility with a beta of 1.17 — expect wider price swings.
INDV is growing revenue faster at 19.2% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
INDV scores higher overall (62/100 vs 57/100), backed by strong 19.5% margins and 19.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Indivior PLC Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?